NORD sends comments to FDA on clinical outcome assessments
Published: Sep 27, 2022
Tagged in: Advancing Rare Disease Research and Regulatory Science, Patient Focused Drug Development
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD sends comments to FDA on clinical outcome assessments
Published: Sep 27, 2022
Tagged in: Advancing Rare Disease Research and Regulatory Science, Patient Focused Drug Development
NORD and 98 organizations send letter to Congressional leadership to resume negotiations to develop a comprehensive FDA user fee package
Published: Aug 1, 2022
Tagged in: User Fee Act
NORD and 70 other organizations urge Senate HELP and House Energy and Commerce leadership to address clinical trial diversity in the PDUFA reauthorization
Published: Jul 11, 2022
Tagged in: User Fee Act, Clinical Trials
NORD and 84 organizations urge Senate HELP leadership to incorporate the RARE Act into the FDA Safety and Landmarks Advancement Act
Published: Jun 3, 2022
Tagged in: RARE Act, Orphan Drug Act, Protecting FDA Standards for Safe and Effective Drugs
NORD and 71 organizations urge Senate HELP committee to incorporate Title V in the House PDUFA bill
Published: Jun 8, 2022
Tagged in: User Fee Act, Clinical Trials
